130 related articles for article (PubMed ID: 32822322)
21. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma.
Caturelli E; Bartolucci F; Biasini E; Vigliotti ML; Andriulli A; Siena DA; Attino V; Bisceglia M
Am J Gastroenterol; 2002 Feb; 97(2):397-405. PubMed ID: 11866279
[TBL] [Abstract][Full Text] [Related]
22. Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection.
Gressner OA; Fang M; Li H; Lu LG; Gressner AM; Gao CF
Clin Chim Acta; 2013 Jun; 421():126-31. PubMed ID: 23501329
[TBL] [Abstract][Full Text] [Related]
23. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma.
Brunt EM; Walsh SN; Hayashi PH; Labundy J; Di Bisceglie AM
Liver Int; 2007 Jun; 27(5):662-71. PubMed ID: 17498252
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical markers for hepatocellular carcinoma prognosis after liver resection and liver transplantation.
Lee SH; Lee JS; Na GH; You YK; Kim DG
Clin Transplant; 2017 Jan; 31(1):. PubMed ID: 27653235
[TBL] [Abstract][Full Text] [Related]
25. Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma.
Heo MJ; Yun J; Kim SG
Arch Pharm Res; 2019 Jan; 42(1):48-62. PubMed ID: 30610616
[TBL] [Abstract][Full Text] [Related]
26. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma.
Yu D; Shi X; Meng G; Chen J; Yan C; Jiang Y; Wei J; Ding Y
Oncotarget; 2015 Apr; 6(10):7619-31. PubMed ID: 25844758
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of (unresectable) hepatocellular carcinoma at an intermediate or advanced stage].
Van Daele D; Belaiche J; Delwaide J; Piront P; De Roover A; Detry O; Honoré P; Polus M
Rev Med Liege; 2009 Mar; 64(3):140-7. PubMed ID: 19418933
[TBL] [Abstract][Full Text] [Related]
28. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
29. The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker.
Carrasco-Torres G; Fattel-Fazenda S; López-Alvarez GS; García-Román R; Villa-Treviño S; Vásquez-Garzón VR
Tumour Biol; 2016 Feb; 37(2):2007-14. PubMed ID: 26337276
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
31. Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection.
Murakami C; Hino K; Korenaga M; Okazaki M; Okuda M; Nukui K; Okita K
J Clin Gastroenterol; 1999 Mar; 28(2):148-52. PubMed ID: 10078824
[TBL] [Abstract][Full Text] [Related]
32. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.
Rastogi A
World J Gastroenterol; 2018 Sep; 24(35):4000-4013. PubMed ID: 30254404
[TBL] [Abstract][Full Text] [Related]
33. Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma.
Wang JH; Wei W; Guo ZX; Shi M; Guo RP
J Transl Med; 2015 Feb; 13():41. PubMed ID: 25638165
[TBL] [Abstract][Full Text] [Related]
34. Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.
Gao R; Cheng J; Fan C; Shi X; Cao Y; Sun B; Ding H; Hu C; Dong F; Yan X
Sci Rep; 2015 Dec; 5():18175. PubMed ID: 26658617
[TBL] [Abstract][Full Text] [Related]
35. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
36. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation.
Zekri Ael-R; Nassar AA; El-Din El-Rouby MN; Shousha HI; Barakat AB; El-Desouky ED; Zayed NA; Ahmed OS; El-Din Youssef AS; Kaseb AO; Abd El-Aziz AO; Bahnassy AA
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6721-6. PubMed ID: 24377595
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular carcinoma and CXCR3 chemokines: a narrative review.
Elia G; Fallahi P
Clin Ter; 2017; 168(1):e37-e41. PubMed ID: 28240761
[TBL] [Abstract][Full Text] [Related]
38. Histopathology of hepatocellular carcinoma.
Paradis V
Recent Results Cancer Res; 2013; 190():21-32. PubMed ID: 22941011
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in molecular biomarkers for patients with hepatocellular carcinoma.
Umeda S; Kanda M; Kodera Y
Expert Rev Mol Diagn; 2019 Aug; 19(8):725-738. PubMed ID: 31248309
[No Abstract] [Full Text] [Related]
40. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
Kazankov K; Rode A; Simonsen K; Villadsen GE; Nicoll A; Møller HJ; Lim L; Angus P; Kronborg I; Arachchi N; Gorelik A; Liew D; Vilstrup H; Frystyk J; Grønbæk H
Scand J Clin Lab Invest; 2016; 76(1):64-73. PubMed ID: 26549495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
